Short answer: FDA's review found no increased risk. In January 2026 FDA asked for the suicidal behavior and ideation warning to be removed from Wegovy, Zepbound and Saxenda after a meta-analysis of 91 placebo-controlled trials with 107,910 people found no higher risk of suicidal thoughts or behavior, or of anxiety, depression, irritability or psychosis. The Wegovy and Zepbound labels show it removed in February 2026. EMA reached a similar view in 2024. FDA still says to report new or worsening depression or mood changes.
When Wegovy, Zepbound and Saxenda were approved for weight reduction, their labels included a warning about possible suicidal thoughts and behavior. FDA says that wording was based on reports seen with a variety of older medicines used or studied for weight loss, and appears on other weight-loss medicines too. FDA says the labels of GLP-1 medicines approved for type 2 diabetes, such as Ozempic and Mounjaro, do not include it.
In July 2023, after receiving reports of suicidal thoughts in people taking GLP-1 medicines, FDA began a closer look. A preliminary review, published in January 2024, found no link in the trial data, but there were too few cases in individual trials to be sure.
To get a more precise answer, FDA pooled 91 placebo-controlled trials across GLP-1 drug programs, covering 107,910 people (60,338 on a GLP-1 medicine and 47,572 on placebo). The results showed no increased risk of suicidal thoughts or behavior, and none for other psychiatric problems including anxiety, depression, irritability or psychosis.
FDA also ran a study of health insurance claims through its Sentinel System, comparing about 1.16 million people with type 2 diabetes who started a GLP-1 medicine with about 1.08 million who started an SGLT2 inhibitor, another diabetes drug class, between 2015 and 2023. After adjusting for differences between the groups, it found no increased risk of intentional self-harm, including in people with both diabetes and obesity. Its review of published studies did not support a causal link either.
On January 13, 2026, FDA asked the makers of Saxenda, Wegovy and Zepbound to remove the warning so all GLP-1 labels say the same thing. The current Wegovy and Zepbound labels list "Suicidal Behavior and Ideation" as removed in 02/2026.
The European Medicines Agency's safety committee (PRAC) reviewed the same question from July 2023, covering dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide. In April 2024 it concluded that the evidence does not support a causal link with suicidal or self-injurious thoughts and actions, and that no change to the product information was needed. The companies continue to monitor these events.
No increased risk across large groups does not mean no one ever feels worse. FDA's advice to patients is to keep taking the medicine as prescribed, discuss concerns with a health care professional, and tell them about new or worsening depression, suicidal thoughts, or any unusual changes in mood or behavior. It tells professionals to refer anyone reporting suicidal thoughts for mental health evaluation.
One mood link is on the labels: the Ozempic, Wegovy, Mounjaro and Zepbound leaflets list anxiety, irritability or mood changes among the signs of low blood sugar, which is more likely with insulin or a sulfonylurea (see low blood sugar on GLP-1 medicines).
Dose Track lets you rate your mood each day next to your dose log, which makes any change easier to describe to your provider.
Read more on Dose Track: GLP-1s and alcohol · Stopping a GLP-1 and weight regain · Wegovy side effects · Zepbound side effects · Saxenda side effects